Takeda and Frazier Healthcare Partners launched Phathom Pharmaceuticals to develop gastrointestinal treatments.
What you should know:
1. Phathom will develop and commercialize Takeda's potassium competitive acid blocker, vonoprazan, in the U.S., Europe and Canada.
2. Frazier led a $90 million financing round supported by several other investors.
3. Phathom then took out a $50 million loan through Silicon Valley Bank to support developmental efforts.